Abstract
Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Current Psychopharmacology
Title:Antipsychotics Management in Addictive Disorders
Volume: 2
Author(s): Pierre Alexis Geoffroy, Benjamin Rolland, Vincent Laprevote and Olivier Cottencin
Affiliation:
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Abstract: Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Export Options
About this article
Cite this article as:
Geoffroy Alexis Pierre, Rolland Benjamin, Laprevote Vincent and Cottencin Olivier, Antipsychotics Management in Addictive Disorders, Current Psychopharmacology 2013; 2 (3) . https://dx.doi.org/10.2174/221155601130200006
DOI https://dx.doi.org/10.2174/221155601130200006 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insight into Cocaine-Induced Neural and Behavioral Adaptations Using Genome-Wide Expression Profiling and Epigenomic Analysis
Current Psychopharmacology Review of Characteristics, Pharmacology, Determination and Pharmacokinetics of Rhaponticin
Mini-Reviews in Organic Chemistry Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
Current Alzheimer Research Rehab of NAD(P)-Dependent Enzymes with NAD(P)-Based Inhibitors
Current Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry A Brief Review of Drug Discovery Research for Human African Trypanosomiasis
Current Medicinal Chemistry AIDS-related Insulin Resistance and Lipodystrophy Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Crystal Engineering to Design of Solids: From Single to Multicomponent Organic Materials
Mini-Reviews in Organic Chemistry Transgenic Mouse Models with Tau Pathology to Test Therapeutic Agents for Alzheimers Disease
Mini-Reviews in Medicinal Chemistry The Role of N-Methyl-D-Aspartate Receptor - Mediated Neurotransmission in Attention Deficit (Hyperactivity) Disorder (ADHD/ADD)
Current Psychopharmacology Retraction Notice: Protein Identification in Sub Proteome Fractions of Breast Cancer Cells by OFFGEL-IEF and iTRAQ Labeling
Current Proteomics Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine Contingency Management for Smoking Cessation: Where Do We Go from Here?
Current Drug Abuse Reviews Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy